V e r s i o n 3 . 0 p r o d u c t i n f o r m a t i o N
What is the ANX?
The ANX, a new & patented heart rate variability (HRV) & respiratory variability-based test. It is the only monitoring technology available that enables clinicians to assess sympathovagal balance in the autonomic nervous system (ANS).
How does ANX technology revolutionize medicine?
Chronic sympathovagal imbalance in the ANS can be the result of autonomic nerve damage along vital neural control paths. Identifying this imbalance early enables physicians to adjust patient treatment to slow or stop nerve damage and before end organ damage occurs, including cardiovascular and non-cardiovascular systems damage. This means sympathovagal assessment can be strategically applied to a broad practice of medicine, including the following applications:
• Diagnosis of disease on an individual patient basis,
• Evaluation and tracking of the severity of disease based on a patient’s own physiologic
• Determination of risk factors and prognosis.
• Monitoring of the effects and titration of medication and other treatment interventions
specifically for the individual.
What is ANX technology, and how does it work?
The ANX is a non-invasive, digital, real-time, HRV & respiratory variability-based monitor of the ANS. Three (3) leads are used to capture EKG & respiratory signals. The ANX measures the ANS as follows:
• Detects & records variations in the R-R, or beat-to-beat, interval and respiratory activity and
plots this data.
• Data undergo spectral analysis to identify high- & low-frequency components of the Heart
Beat Interval (HBI) plot.
• Performs spectral analysis of the respiratory signal to precisely locate the parasympathetic, or
high-frequency, component of the HBI signal.
• Respiratory activity analysis provides independent and more specific measurements of
sympathetic activity and parasympathetic activity: at rest to determine baseline power
and balance between the branches, during individual challenges to each branch, and a
combined challenge to both branches to detect degrees of neuropathy or ANS branch
suppression or excess.
What does the ANX have that no other technology can provide?
• The ANX incorporates the respiratory signal (ANSAR’s patented MIT-based technology) into frequency analysis of HRV. To accurately locate parasympathetic activity, the breathing rate must be known. The location of parasympathetic activity is not always fixed within the standard HF bandwidth (e.g., during deep breathing the rate slows and parasympathetic activity moves into the low frequency area—0.04 - 0.10 Hz).
• HRV and respiratory signals are analyzed through Continuous Wavelet Transform (CWT)
signal processing. This established analysis allows the ANX to perform transient frequency
analyses. CWT is better suited to human biomedical applications, because of the transient
nature of human biomedical systems.
• The ANX includes a proprietary algorithm using spline interpolation to correct for ectopic
beats throughout the monitoring cycle.
• The ANX generates quantitative (numerical) & qualitative (graphical) data. Data include standard time and frequency domain indices (historical comparisons), along with ANSAR’s new frequency analysis incorporating the respiratory signal (separation and analysis of both Vagal and sympathetic activity). This comprehensive, multi-parameter data analysis gives confidence to interpretation and enables clinicians to correlate data with over 30 years of HRV data in the clinical literature.
• Time-Frequency Color Map – This is a 3-dimensional color map containing all time and
frequency domain HRV information. At a glance, this color map provides the clinician with a
complete picture of ANS functioning over the entire frequency spectrum throughout the
• A Trends plot contains two curves representing the instantaneous changes in sympathetic
and parasympathetic activity over the course of the test.
• ANSAR’s 15.5-minute test can be performed by any technician, in any location, and provides
numerical and graphical interpretation for clinicians to review in their office.
Case Study: 79-year-old diabetic male with cancer, history of CABG & mild hypertension with mild peripheral edema.
ANX Test 1: (diltiazem hydrochloride 180mg daily):
RV during testing is minimal. (See heart rate plot below.) Clinical literature states that when the parasympathetic (RFa) tone drops below 0.1, a patient is at risk of sudden death.
Please refer to Y-axes for scaling when comparing these graphs with those below.)
HRV is extremely low. Total tone at baseline Vagal tone at baseline Sympathetic tone at baseline
Beat-to-beat variations (A=0.04) is very low (A=0.02) is very low. (A=0.02) is very low.
range from 0-3 beats. (well below 0.1). Response to Deep Response to Valsalva
Breathing (B=0.11) is slight. (D=0.42) is slight.
ANX Test 2: (diltiazem hydrochloride D/C x 3 weeks – BP stable 132/72 – Lasix 20mg x 3 weeks for edema):
RV is significantly improved throughout the entire test. Although the patient’s parasympathetic and especially sympathetic function are still depressed, results indicate he is now out of the high-risk category. ANS tone in the parasympathetic (RFa) branch is improved by 782% during Deep Breathing, within just 10 weeks of medication change. Total tone at baseline increased from 0.04 to 1.86, improving by 4,550%.
HRV is significantly Total tone is significantly Vagal tone is significantly Sympathetic tone at baseline
improved over Test 1. improved at baseline improved at baseline (A=1.62). (A=0.24) is improved by
Beat-to-beat variations (A=1.86). Response to Deep Breathing 1100%.
now range from (B=0.97) is improved over
10-12 beats. Test 1.
s y s t e m s p e c i f i c a t i o ns ANX 3.0
Heart Rate: ±1% accuracy
Test Duration: 15.5 minutes
Ectopic Beats: Spline Interpolated
Frequency Domain: LFa, RFa, LFa/RFa, LF, HF, LFnu, HFnu, LF/HF, VLF
Premature Beats: Counted
Technology: Respiration-Incorporated HRV
Time Domain: E/I Ratio, Valsalva Ratio, 30:15 Ratio, sdNN, rmsSD,
Continuous Wavelet Transform
pNN50, Histogram & Lorenz plot of R-R Intervals
Time-Frequency Color Mapping
Tests: Resting Baseline, Deep Breathing
Report Generation: Both Qualitative & Quantitative Analyses Valsalva, Stand
Printed immediately after test or stored electronically
The ANSAR Group • 240 South 8th Street • Philadelphia, Pennsylvania 19107
888 883 7804 • 215 922 6088 • www.ans-hrv.com • email@example.com
29 August 2001